Fresenius SE Return on Tangible Equity 2016-2023 | FSNUY
Current and historical return on tangible equity values for Fresenius SE (FSNUY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Fresenius SE Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-09-30 |
$0.27B |
$12.95B |
62.71% |
| 2023-06-30 |
$1.03B |
$-4.07B |
-27.59% |
| 2023-03-31 |
$1.35B |
$-3.35B |
-38.72% |
| 2022-12-31 |
$1.45B |
$-3.82B |
-42.58% |
| 2022-09-30 |
$1.77B |
$-3.72B |
-50.90% |
| 2022-06-30 |
$1.93B |
$-3.09B |
-52.22% |
| 2022-03-31 |
$2.09B |
$-2.95B |
-49.58% |
| 2021-12-31 |
$2.15B |
$-4.12B |
-46.63% |
| 2021-09-30 |
$2.07B |
$-4.63B |
-43.03% |
| 2021-06-30 |
$2.08B |
$-5.17B |
-40.91% |
| 2021-03-31 |
$1.97B |
$-4.53B |
-38.96% |
| 2020-12-31 |
$1.95B |
$-4.93B |
-36.49% |
| 2020-09-30 |
$2.03B |
$-5.74B |
-36.76% |
| 2020-06-30 |
$2.02B |
$-5.00B |
-36.65% |
| 2020-03-31 |
$2.10B |
$-5.71B |
-35.94% |
| 2019-12-31 |
$2.11B |
$-5.63B |
-35.78% |
| 2019-09-30 |
$2.12B |
$-5.75B |
-25.13% |
| 2019-06-30 |
$2.12B |
$-6.29B |
-19.27% |
| 2019-03-31 |
$2.37B |
$-5.91B |
-17.45% |
| 2018-12-31 |
$2.39B |
$-15.86B |
-14.55% |
| 2018-09-30 |
$2.41B |
$-15.89B |
-16.75% |
| 2018-06-30 |
$2.39B |
$-16.56B |
-19.02% |
| 2018-03-31 |
$2.10B |
$-17.46B |
-20.28% |
| 2017-12-31 |
$2.05B |
$-7.62B |
-25.81% |
| 2017-09-30 |
$1.93B |
$-8.55B |
-27.02% |
| 2017-06-30 |
$1.90B |
$-7.86B |
-31.20% |
| 2017-03-31 |
$1.85B |
$-7.74B |
-33.97% |
| 2016-12-31 |
$1.76B |
$-4.34B |
-37.30% |
| 2016-09-30 |
$1.68B |
$-4.44B |
-33.31% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$17.090B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
